Handelsbanken Fonder AB Decreases Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Handelsbanken Fonder AB lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 10.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 104,117 shares of the company’s stock after selling 12,398 shares during the quarter. Handelsbanken Fonder AB owned about 0.08% of Henry Schein worth $7,883,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in Henry Schein by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock worth $353,898,000 after purchasing an additional 53,506 shares in the last quarter. American Century Companies Inc. lifted its stake in Henry Schein by 7.3% in the 3rd quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock worth $350,392,000 after purchasing an additional 322,649 shares in the last quarter. Northern Trust Corp lifted its stake in Henry Schein by 2.8% in the 3rd quarter. Northern Trust Corp now owns 1,647,889 shares of the company’s stock worth $122,356,000 after purchasing an additional 45,561 shares in the last quarter. Lazard Asset Management LLC lifted its stake in Henry Schein by 1,303.3% in the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock worth $92,614,000 after purchasing an additional 1,158,451 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Henry Schein by 1.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,107,940 shares of the company’s stock worth $82,265,000 after purchasing an additional 11,490 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other news, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at approximately $15,585,125.94. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Price Performance

Shares of HSIC stock opened at $73.21 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The company has a market capitalization of $9.41 billion, a P/E ratio of 23.24, a P/E/G ratio of 1.80 and a beta of 0.87. The company’s 50-day simple moving average is $74.29 and its two-hundred day simple moving average is $72.43. Henry Schein, Inc. has a one year low of $60.01 and a one year high of $85.39.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The company had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. During the same quarter in the prior year, the company earned $1.21 earnings per share. Henry Schein’s revenue was down 10.5% on a year-over-year basis. As a group, equities analysts anticipate that Henry Schein, Inc. will post 5.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on HSIC. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b-” rating in a report on Monday, February 26th. Leerink Partnrs restated a “market perform” rating on shares of Henry Schein in a report on Monday, February 26th. JPMorgan Chase & Co. boosted their target price on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Barrington Research boosted their target price on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Finally, Jefferies Financial Group boosted their target price on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Henry Schein has a consensus rating of “Hold” and an average price target of $81.09.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.